Share Market Newspaper

Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

October 26
22:56 2023
Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Moderate to Severe Inflammatory Acne Vulgaris Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Moderate to Severe Inflammatory Acne Vulgaris pipeline landscape. It covers the Moderate to Severe Inflammatory Acne Vulgaris Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Moderate to Severe Inflammatory Acne Vulgaris pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Moderate to Severe Inflammatory Acne Vulgaris Pipeline Report

  • DelveInsight’s Moderate to Severe Inflammatory Acne Vulgaris pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Moderate to Severe Inflammatory Acne Vulgaris treatment.
  • The leading companies working in the Moderate to Severe Inflammatory Acne Vulgaris Market include Sagimet Biosciences, Boston Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Botanix Pharmaceuticals, Cutia Therapeutics, Janssen Research & Development LLC, Biofrontera Bioscience GmbH, Braintree Laboratories, and others.
  • Promising Moderate to Severe Inflammatory Acne Vulgaris Pipeline Therapies in the various stages of development include BPX-01 1% Minocycline Topical Gel, CJM112, LYS006 20 mg, Minocycline, RA-18C3, and others.
  • August 2023: Novartis Pharmaceuticals announced a study of phase 2 clinical trials for LYS006 20 mg. The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development. This was a randomized, placebo-controlled, subject- and investigator-blinded, multicenter, nonconfirmatory, parallel group, and proof-of-concept study in adult patients with moderate to severe inflammatory acne. After an initial screening period (up to 4 weeks), subjects were treated with LYS006 or matching placebo for 12 consecutive weeks to assess preliminary clinical efficacy, safety, and tolerability in the targeted subject population.
  • July 2022: BioPharmX Inc. announced a study of Phase 2 clinical trials for Minocycline. This is a multi center open label study intended to provide photo documentation and time to response data for BPX-01 1 and 2% minocycline topical gel for the treatment of moderate to severe non-nodular inflammatory acne vulgarism. This was a 12-week, multi-center, open label, two-arm study. Subjects will be assigned to treatment with 1% or 2% BPX-01 gel. Subjects will apply 1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night for 12 weeks. Lesion counts, IGA, and Patient-Reported Outcomes (PGI-S and PGI-I) will be performed to assess efficacy. Photographs will be taken to document treatment effect.

 

Request a sample and discover the recent advances in Moderate to Severe Inflammatory Acne Vulgaris Treatment Drugs @ Moderate to Severe Inflammatory Acne Vulgaris Pipeline Report

 

In the Moderate to Severe Inflammatory Acne Vulgaris pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Moderate to Severe Inflammatory Acne Vulgaris NDA approvals (if any), and product development activities comprising the technology, Moderate to Severe Inflammatory Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Moderate to Severe Inflammatory Acne Vulgaris Overview

Acne vulgaris may be defined as any disorder of the skin whose initial pathology is the microscopic microcomedo. The microcomedo may evolve into visible open comedones (“blackheads”) or closed comedones (“whiteheads”). Subsequently, inflammatory papules, pustules, and nodules may develop.

 

Find out more about Moderate to Severe Inflammatory Acne Vulgaris Therapeutics Assessment @ Moderate to Severe Inflammatory Acne Vulgaris Preclinical and Discovery Stage Products

 

Moderate to Severe Inflammatory Acne Vulgaris Emerging Drugs Profile

  • TVB-2640: Sagimet Biosciences
  • BOS 356: Boston Pharmaceuticals

 

Moderate to Severe Inflammatory Acne Vulgaris Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the Moderate to Severe Inflammatory Acne Vulgaris therapies. The Moderate to Severe Inflammatory Acne Vulgaris companies which have their Moderate to Severe Inflammatory Acne Vulgaris drug candidates in the most advanced stage, i.e. phase II include, Sagimet Biosciences.

 

DelveInsight’s Moderate to Severe Inflammatory Acne Vulgaris pipeline report covers around 15+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Moderate to Severe Inflammatory Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Moderate to Severe Inflammatory Acne Vulgaris Pipeline Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Moderate to Severe Inflammatory Acne Vulgaris Pipeline Therapies @ Moderate to Severe Inflammatory Acne Vulgaris Clinical Trials Assessment

 

Scope of the Moderate to Severe Inflammatory Acne Vulgaris Pipeline Report

  • Coverage- Global
  • Moderate to Severe Inflammatory Acne Vulgaris Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Moderate to Severe Inflammatory Acne Vulgaris Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Moderate to Severe Inflammatory Acne Vulgaris Companies- Sagimet Biosciences, Boston Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Botanix Pharmaceuticals, Cutia Therapeutics, Janssen Research & Development LLC, Biofrontera Bioscience GmbH, Braintree Laboratories, and others.
  • Moderate to Severe Inflammatory Acne Vulgaris Pipeline Therapies- BPX-01 1% Minocycline Topical Gel, CJM112, LYS006 20 mg, Minocycline, RA-18C3, and others.

 

Dive deep into rich insights for new drugs for Moderate to Severe Inflammatory Acne Vulgaris Treatment, Visit @ Moderate to Severe Inflammatory Acne Vulgaris Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Moderate to Severe Inflammatory Acne Vulgaris: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Moderate to Severe Inflammatory Acne Vulgaris– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Drug name : Company name
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. TVB-2640: Sagimet Biosciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Moderate to Severe Inflammatory Acne Vulgaris Key Companies
  21. Moderate to Severe Inflammatory Acne Vulgaris Key Products
  22. Moderate to Severe Inflammatory Acne Vulgaris – Unmet Needs
  23. Moderate to Severe Inflammatory Acne Vulgaris – Market Drivers and Barriers
  24. Moderate to Severe Inflammatory Acne Vulgaris – Future Perspectives and Conclusion
  25. Moderate to Severe Inflammatory Acne Vulgaris Analyst Views
  26. Moderate to Severe Inflammatory Acne Vulgaris Key Companies
  27. Appendix

 

For further information on the Moderate to Severe Inflammatory Acne Vulgaris Pipeline therapeutics, reach out to Moderate to Severe Inflammatory Acne Vulgaris Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/moderate-to-severe-inflammatory-acne-vulgaris-market